Celebrex Set For Rebound; Silver Lining For Pfizer After Bextra Pulled

Celebrex is in a good position to reclaim its position as the leading anti-arthritic therapy following the conclusion of FDA's safety review of the non-steroidal anti-inflammatory drug class

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet